Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
Highlands Ranch Hospital - CU Med Clinics, University of Colorado Hospital
|
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB
AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB
IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC
MELANOMA
Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital
|
IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
CTRC Inpatient, University of Colorado Hospital
|
Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL-MF)
Department Specific Free Standing Clinic, University of Colorado Hospital
Castle Biosciences, Incorporated (CSTL) recently developed and validated a 35-GEP test to aid in the diagnosis of difficult- to-diagnose primary cutaneous melanocytic neoplasms and to improve accuracy when used in combination with currently applied diagnostic tools. Ambiguous lesions repre...
|
S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726)
(BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Rocky Mountain Regional VA Medical Center
|
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-Escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination with Atezolizumab (Part 2)
University of Colorado Hospital
Part 1 of the study is open to all solid tumors. Part 2 of the study will evaluate the safety, tolerability and preliminary efficacy of
DSP107, administered either as monotherapy or in combination with atezolizumab.
The study will enrol subjects with NSCLC that is wildtype for actionable...
|
AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
Financial Burden Associated with Retirement among Cancer Survivors
|
Evaluation of Sun Protection Education using the Reveal Imager Photo-aging and the SPA Questionnaire
Department Specific Free Standing Clinic, University of Colorado Cancer Center, University of Colorado Hospital
|
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital
|
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
051/02 A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Childrens Hospital Colorado
|
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer (ORIEN)
Cherry Creek Medical Center, Highlands Ranch Hospital, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital
This study plans to learn more about how to improve standard cancer care. Cancer is a tough disease to treat because few cancers behave in the same way. Recent research suggests that information stored in your blood, tissues and body fluids can be studied to change the way we treat cancer ...
|
A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
Highlands Ranch Hospital, University of Colorado Hospital
|
